PERSONALIZED MEDICINE IN BRONCHIAL OBSTRUCTION SYNDROME

Download full text PDF
Issue: 
7
Year: 
2015

N. Berdnikova, PhD; M. Zhuravleva, MD; V. Kukes, MD, Academician of Russian Academy of Sciences I.M. Sechenov First Moscow State Medical University

Bronchial obstruction syndrome (BOS) is mainly caused by asthma, obstructive pulmonary disease (COPD), or emphysema. Asthma and COPD can be effectively treated by bronchodilator therapies delivered by inhalation. Inhalation of beta2adrenergic agonist and combination of the anticholinergic agent and the beta2adrenergic agonist is advantageous for the treatment of any bronchoobstructive syndrome prevention and exacerbation of asthma and COPD.
Keywords: 
bronchial obstruction syndrome
asthma
COPD
beta2-adrenergic agonist
anticholinergic agent

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Shmelev E.I. Bronho-
  2. obstruktivnyj sindrom – universal'noe patologicheskoe sostojanie v pul'monologii // Meditsina neotlozhnyh sostojanij. – 2006; 5 (6): 8–13. URL http://www.mif-ua.com/
  3. Chuchalin A.G. Hronicheskie obstruktivnye bolezni legkih / SPb: Nevskij dialekt, 1998; s. 234–40, 436–40.
  4. Global Initiative for asthma (GINA), update 2014. URL http: // www.ginasthma.org
  5. Global Initiative for COPD, update 2014. URL http: //www.goldcopd.org/guidelines-resources.htm
  6. Holland A., Smith F., Penny K. et al. Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units (Review) // The Cochrane Collaboration and published in The Cochrane Library. – 2013; Issue 6. http://www.update-software.com/
  7. Green S., Turki J., Vegarno P. et al. Influencce of β2-adrenergic receptor genotypes on signal transduction in human airways smooth muscle cells // Am. J. Respir. Cell Mol. Biol. – 1995; 13: 25–33.
  8. Metzger N., Kockler D., Gravatt L. Confirmed beta16Arg/Arg polymorphism in a patient with uncontrolled asthma // Ann. Pharmacother. – 2008; 42 (6): 874–81.
  9. Ligett S. Pharmacogenetics or β1- and β2-adrenergic receptors // Pharmacology. – 2002; 137: 1213–6.
  10. Bleecker E., Posthma D., Lawrance R. et al. Effect of ADRB2 polymorphism on responce to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomized studies // Lancet. – 2007; 370: 2118–25.
  11. Genetika bronholegochnyh zabolevanij. Pod red. V.P. Puzyreva, L.M. Ogorodovoj / M.: Atmosfera, 2010; s. 78–95.
  12. Tse S., Tantisira K., Weiss S. The Pharmacogenetics and Pharmacogenomics of Asthma Therapy // Pharmacogenomics J. – 2011; 11 (6): 383–92.
  13. Westby M. Anticholinergic agents for chronic asthma in adults // Cochrane Database Syst. Rev. – 2004; 3 (Art No CD003269).
  14. Carstairs J., Nimmo A., Barnes P. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung // Am. Rev. Respir. Dis. – 1985; 132 (3): 541–7.
  15. Bronhial'naja astma. Pod red. akad. RAMN A.G. Chuchalina. V 2-h t. / M.: Agar, 1997; T. 2.: s. 269–91, 303–21.
  16. Tatsuya Haga. Molecular properties of muscarinic acetylcholine receptors // Proc. Jpn. Acad. Ser. Phys. Biol. Sci. – 2013; 89 (6): http://www.ncbi.nlm.nih.gov/pmc/issues/226608/11 PMC3749793
  17. Mak J., Barnes P. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung // Am. Rev. Respir. Dis. – 1990; 141 (6): 1559–68.
  18. Klinicheskaja farmakologija. Pod red. akad. RAN, prof. V.G. Kukesa / M.: GEOTAR-Media, 2015; s. 526–47.
  19. Zyrjanov S.K., Ajsanov Z.R. Vosproizvedennye ingaljatsionnye lekarstvennye sredstva: kak otsenit' ih svojstva? // Pul'monologija. – 2012; 3: http://journal.pulmonology.ru/index.php/pulm/article/viewFile/92/91
  20. Fuglsang A. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD // J. Aerosol. Med. Pulm. Drug. Deliv. – 2012; 25 (4): 243–7.
  21. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic, equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents http://www.ema.europa.eu/
  22. Zyrjanov S.K., Galeeva Zh.A., Belousov Ju.B. Kachestvennye generiki dlja lechenija bronhoobstruktivnyh zabolevanij: svet v kontse tonnelja est'! // Lechaschij vrach. – 2014; 11: http://http://www.lvrach.ru/